CHMP positive for combination Lynparza (olaparib) with durvalumab for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient.- AstraZeneca + Merck Inc.
On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lynparza.
The marketing authorisation holder for this medicinal product is AstraZeneca AB.
The CHMP adopted a new indication as follows: Endometrial cancer ; Lynparza in combination with durvalumab is indicated for the maintenance treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) whose disease has not progressed on first-line treatment with durvalumab in combination with carboplatin and paclitaxel.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.